1901 West 47th Place
Kansas City, KS 66205
United States
913 942 2300
https://www.cingulate.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 13
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Shane J. Schaffer Pharm.D., PharmD | CEO & Chairman of the Board | 491,96k | S.O. | 1975 |
Dr. Laurie A. Myers M.B.A., Ph.D. | Executive VP & COO | 415,17k | S.O. | 1957 |
Dr. Matthew N. Brams M.D. | Executive VP & Chief Medical Officer | 244,79k | S.O. | 1964 |
Ms. Jennifer L. Callahan CPA | Senior VP, CFO & Secretary | S.O. | S.O. | 1971 |
Dr. Raul R. Silva M.D. | Executive VP & Chief Science Officer | S.O. | S.O. | 1958 |
Thomas Dalton | Vice President of Investor & Public Relations | S.O. | S.O. | S.O. |
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
L’ISS Governance QualityScore de Cingulate Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..